Distribution, cellular localization, and therapeutic potential of the tumor-associated antigen Ku70/80 in glioblastoma multiforme

Journal of Neuro-Oncology

Volumn 97, Issue 2, 2010, Pages 207-215

  Persson, Oscar ^a   Salford, Leif G ^a   Fransson, Johan ^b   Widegren, Bengt ^a,b   Borrebaeck, Carl A K ^b   Holmqvist, Bo ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Glioma; Immunotherapy; Ku70 80; Tumor antigen

Indexed keywords

INCA X; KU ANTIGEN; KU80 ANTIGEN; ONCOPROTEIN; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GRADING; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA REPAIR; ENDOCYTOSIS; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; INTERNALIZATION; PROTEIN LOCALIZATION;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; ANTIGENS, NUCLEAR; BRAIN NEOPLASMS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MICROSCOPY, CONFOCAL;

EID: 77950460434     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-0013-3     Document Type: Article

References (23)

1. Lambert JM (2005) Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol 5:543-549 (Pubitemid 41258574)
2. Sharkey RM, Goldenberg DM (2006) Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 56:226-243 (Pubitemid 44175051)
3. Shimamura T, Husain SR, Puri RK (2006) The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy. Neurosurg Focus 20:E11
4. Chari RV (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 41:98-107
5. Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ et al (1998) Iodine-131-labeled anti-tenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol 16: 2202-2212
6. Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS, Herndon JE II, Kunwar S, Marcus S, McLendon RE, Paolino A et al (2003) Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 65:27-35
7. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD (2008)Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 20: 267-275
8. Fransson J, Borrebaeck CA (2006) The nuclear DNA repair protein Ku70/80 is a tumor-associated antigen displaying rapid receptor mediated endocytosis. Int J Cancer 119:2492-2496
9. Muller C, Paupert J, Monferran S, Salles B (2005) The double life of the Ku protein: facing the DNA breaks and the extracellular environment. Cell Cycle 4:438-441
10. Mimori T, Hardin JA, Steitz JA (1986) Characterization of the DNA-binding protein antigen Ku recognized by autoantibodies from patients with rheumatic disorders. J Biol Chem 261:2274-2278
11. Monferran S, Paupert J, Dauvillier S, Salles B, Muller C (2004) The membrane form of the DNA repair protein Ku interacts at the cell surface with metalloproteinase 9. EMBO J 23:3758-3768 (Pubitemid 39389707)
12. Prabhakar BS, Allaway GP, Srinivasappa J, Notkins AL (1990) Cell surface expression of the 70-kD component of Ku, a DNA-binding nuclear autoantigen. J Clin Investig 86:1301-1305
13. Ginis I, Faller DV (2000) Hypoxia affects tumor cell invasiveness in vitro: the role of hypoxia-activated ligand HAL1/13 (Ku86 autoantigen). Cancer Lett 154:163-174
14. Ginis I, Mentzer SJ, Li X, Faller DV (1995) Characterization of a hypoxia-responsive adhesion molecule for leukocytes on human endothelial cells. J Immunol 155:802-810
15. Lynch EM, Moreland RB, Ginis I, Perrine SP, Faller DV (2001) Hypoxia-activated ligand HAL-1/13 is lupus autoantigen Ku80 and mediates lymphoid cell adhesion in vitro. Am J Physiol Cell Physiol 280:C897-C911
16. Dalziel RG, Mendelson SC, Quinn JP (1992) The nuclear autoimmune antigen Ku is also present on the cell surface. Autoim-munity 13:265-267
17. Salford LG, Siesjo P, Skagerberg G, Persson BRR, Larsson E-M, Lindvall M, Visse E, Widegren B (2002) Search for effective therapy against glioblastoma multiforme\clinical immunisation with autologous glioma cells transduced with the human interferon-gamma gene. Int Congr Ser 1247:211-220
18. Bergamaschi G, Perfetti V, Tonon L, Novella A, Lucotti C, Danova M, Glennie MJ, Merlini G, Cazzola M (1996) Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis. Br J Haematol 93:789-794
19. Kohls MD, Lappi DA (2000) Mab-ZAP: a tool for evaluating antibody efficacy for use in an immunotoxin. Biotechniques 28: 162-165
20. Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vre-denburgh JJ, Rich JN (2007) Molecularly targeted therapy for malignant glioma. Cancer 110:13-24
21. Zalutsky MR, Moseley RP, Coakham HB, Coleman RE, Bigner DD (1989) Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 49: 2807-2813
22. Rainov NG, Gorbatyuk K, Heidecke V (2008) Clinical trials with intracerebral convection-enhanced delivery of targeted toxins in malignant glioma. Rev Recent Clin Trials 3:2-9
23. Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Friedman AH, Friedman HS, Greer K, Herndon JE II, Kunwar S, McLendon RE, Paolino A et al (2008) Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro-oncology 10:320-329